Amicus Therapeutics upgraded to Buy from Hold, PT raised to $14.
ByAinvest
Thursday, Sep 18, 2025 6:01 am ET1min read
FOLD--
The upgrade comes on the heels of recent positive developments, including the presentation of four-year efficacy and safety data for cipaglucosidase alfa-atga plus miglustat in adults with late-onset Pompe disease at the International Congress of Inborn Errors of Metabolism in Kyoto, Japan. The results highlighted the sustained effectiveness and safety of the therapy across diverse patient groups, underscoring its potential for long-term medical impact [1].
Analysts have cited the new data as a key factor in the upgrade, noting that it supports Amicus Therapeutics' growth narrative and may reinforce confidence in its product portfolio. However, they also acknowledge that the near-term catalyst of broad global uptake remains uncertain, and that the biggest risk of revenue concentration and competition in rare disease markets persists [1].
The upgrade to "Buy" also reflects the company's progress in reducing its losses. Amicus Therapeutics reported a loss of $38 million in the latest trailing-twelve-month period, compared to a loss of $56 million in the full financial year. Analysts anticipate the company to incur a final loss in 2025 before generating positive profits of $89 million in 2026, with the company projected to breakeven just over a year from today [2].
However, investors should be aware of the company's high debt-to-equity ratio, currently at 192%, which increases the risk of investing in the loss-making company. Effective capital management will be crucial for the company's financial sustainability [2].
In conclusion, the upgrade to "Buy" and the raised price target reflect a positive outlook on Amicus Therapeutics' prospects, driven by recent positive developments and analyst confidence in the company's growth trajectory. However, investors should remain vigilant regarding the company's high debt levels and the risks associated with revenue concentration in rare disease markets.
Amicus Therapeutics upgraded to Buy from Hold, PT raised to $14.
Amicus Therapeutics (NASDAQ: FOLD) has received a significant boost in analyst sentiment, with the stock upgraded to a "Buy" rating from "Hold" by a leading financial institution. The price target for the biotechnology company has also been raised to $14, reflecting a positive outlook on the company's prospects [2].The upgrade comes on the heels of recent positive developments, including the presentation of four-year efficacy and safety data for cipaglucosidase alfa-atga plus miglustat in adults with late-onset Pompe disease at the International Congress of Inborn Errors of Metabolism in Kyoto, Japan. The results highlighted the sustained effectiveness and safety of the therapy across diverse patient groups, underscoring its potential for long-term medical impact [1].
Analysts have cited the new data as a key factor in the upgrade, noting that it supports Amicus Therapeutics' growth narrative and may reinforce confidence in its product portfolio. However, they also acknowledge that the near-term catalyst of broad global uptake remains uncertain, and that the biggest risk of revenue concentration and competition in rare disease markets persists [1].
The upgrade to "Buy" also reflects the company's progress in reducing its losses. Amicus Therapeutics reported a loss of $38 million in the latest trailing-twelve-month period, compared to a loss of $56 million in the full financial year. Analysts anticipate the company to incur a final loss in 2025 before generating positive profits of $89 million in 2026, with the company projected to breakeven just over a year from today [2].
However, investors should be aware of the company's high debt-to-equity ratio, currently at 192%, which increases the risk of investing in the loss-making company. Effective capital management will be crucial for the company's financial sustainability [2].
In conclusion, the upgrade to "Buy" and the raised price target reflect a positive outlook on Amicus Therapeutics' prospects, driven by recent positive developments and analyst confidence in the company's growth trajectory. However, investors should remain vigilant regarding the company's high debt levels and the risks associated with revenue concentration in rare disease markets.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet